Skip to main content
Code
2024 ABPI Code of Practice launched, with a new constitution and procedure for the PMCPA
2024 Interactive ABPI Code of Practice
Documents outlining the changes to the ABPI Code
Previous Codes of Practice
Guidance and Q&As
Guidance
Q&As by Topic OR Clause
2024 Code Clause 12 Q&As
Abridged complaints procedure Q&As
2024 Code Clause 10.4 Q&As
Cases
Ongoing cases
Completed cases
Advertised Sanctions
Complaints procedure
Make a complaint
Responding to a complaint
Abridged complaints procedure
Intercompany complaints
Intercompany dialogue
Compliance with intercompany undertakings
Appeal procedures
Administrative charges
Sanctions
Privacy Policy for Complaints
Search the site
About us
Media
Publications
Training
Contact us
eAlert
Code
2024 ABPI Code of Practice launched, with a new constitution and procedure for the PMCPA
2024 Interactive ABPI Code of Practice
Documents outlining the changes to the ABPI Code
Previous Codes of Practice
Guidance and Q&As
Guidance
Q&As by Topic OR Clause
2024 Code Clause 12 Q&As
Abridged complaints procedure Q&As
2024 Code Clause 10.4 Q&As
Cases
Ongoing cases
Completed cases
Advertised Sanctions
Complaints procedure
Make a complaint
Responding to a complaint
Abridged complaints procedure
Intercompany complaints
Intercompany dialogue
Compliance with intercompany undertakings
Appeal procedures
Administrative charges
Sanctions
Privacy Policy for Complaints
AUTH/3879/2/24 - Complainant v Pfizer
Alleged promotion of talazoparib on LinkedIn
Received
09 February 2024
Case number
AUTH/3879/2/24
Status
Breach ruled, case report pending
Case summary
Full report
Case Summary
Ongoing cases
